| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/23/2013 | US8425894 Use of oligomers of lactic acid in the treatment of gynaecological disorders |
| 04/23/2013 | US8425893 Polyurethanes for osteoimplants |
| 04/23/2013 | US8425892 Extended, controlled-release pharmaceutical compositions using charged polymers |
| 04/23/2013 | US8425891 UV-absorbers for ophthalmic lens materials |
| 04/23/2013 | US8425890 Odor-controlling bodily fluid absorber |
| 04/23/2013 | US8425459 Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
| 04/23/2013 | CA2724905C Method of treating burns using avermectin compound |
| 04/23/2013 | CA2709202C Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
| 04/23/2013 | CA2697081C 5-(4-(haloalkoxy)phenyl)pyrimidine-2-amine compounds and compositions as kinase inhibitors |
| 04/23/2013 | CA2696984C Improved pharmaceutical composition containing a selective estrogen receptor modulator and method for the preparation thereof |
| 04/23/2013 | CA2694567C Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity and intermediate thereof |
| 04/23/2013 | CA2658361C Ophthalmic formulations for the treatment of inflammation |
| 04/23/2013 | CA2634168C Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof |
| 04/23/2013 | CA2623047C 7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazinyl]ethyl]-2-(1-propynyl)-7h-pyrazolo-[4,3-e]-[1,2,4]-triazolo-[1,5-c]-pyrimidin-5 amine |
| 04/23/2013 | CA2610042C 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
| 04/23/2013 | CA2603902C Ophthalmic formulations and uses thereof |
| 04/23/2013 | CA2595208C Therapeutic agents for sensory disorders |
| 04/23/2013 | CA2594280C 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists |
| 04/23/2013 | CA2588911C Therapeutic nutrient compositions or combinations and methods of their use |
| 04/23/2013 | CA2588396C 17,20(e)-dehydro vitamin d analogs and their uses |
| 04/23/2013 | CA2581999C Preparation of suspension aerosol formulations |
| 04/23/2013 | CA2581125C Modified poly(ethylene oxide-amino acid) copolymer, micelle preparation, and anticancer agent containing the same |
| 04/23/2013 | CA2580639C Stable dosing form of phenylalanine derivatives |
| 04/23/2013 | CA2577415C Enhancement of antitubercular activity of extracts of salicornia brachiata |
| 04/23/2013 | CA2571558C Novel uses of porphyrin compounds |
| 04/23/2013 | CA2569124C N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| 04/23/2013 | CA2565632C Adamantyl pyrrolidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
| 04/23/2013 | CA2557989C Sulfated oligosaccharide derivatives |
| 04/23/2013 | CA2556069C Compounds having antitumor activity |
| 04/23/2013 | CA2555712C Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein |
| 04/23/2013 | CA2552311C Obesity and metabolic syndrome treatment with tanshinone derivatives which increase metabolic activity |
| 04/23/2013 | CA2549954C Derivatives of 1,4-diazabicyclo[3.2.1]octanecarboxamide, preparation method thereof and use of same in therapeutics |
| 04/23/2013 | CA2548276C Keto lactam compounds and use thereof |
| 04/23/2013 | CA2546189C Inhibitors of the mutant form of kit |
| 04/23/2013 | CA2542650C Bridged ring structures as pharmaceutical agents |
| 04/23/2013 | CA2539277C Aminoalkanol derivatives |
| 04/23/2013 | CA2535185C 2-methylene-19-nor-vitamin d2 compounds |
| 04/23/2013 | CA2516331C Combination therapy using glycosaminoglycans and therapeutic agents for the treatment of respiratory disorders |
| 04/23/2013 | CA2515761C Use of artemisinin for treating tumors induced by oncogenic viruses and for treating viral infections |
| 04/23/2013 | CA2513123C Hiv inhibiting 1,2,4-triazines |
| 04/23/2013 | CA2494764C Treatment of melanoma by reduction in clusterin levels |
| 04/23/2013 | CA2473212C Pharmaceutical composition which improves in vivo gene transfer |
| 04/23/2013 | CA2471355C Substituted diketopiperazines as oxytocin antagonists |
| 04/23/2013 | CA2458394C Lipophilic drug compositions |
| 04/23/2013 | CA2436245C Medicament for protection in radiotherapy |
| 04/23/2013 | CA2386990C Treatments based on discovery that nitric oxide synthase is a paraquat diaphorase |
| 04/22/2013 | DE202006021164U1 Basismaterial für die Herstellung insbesondere von Lebens- und Futtermitteln Base material for the production of particular food and feed |
| 04/21/2013 | CA2851104A1 Methods for treating hcv |
| 04/21/2013 | CA2811250A1 Methods for treating hcv |
| 04/21/2013 | CA2811203A1 Methods for treating hcv |
| 04/18/2013 | WO2013056264A2 Systems and methods for predicting response to anti-androgen therapy for the treatment of androgenetic alopecia |
| 04/18/2013 | WO2013056246A1 Buffered oxygen therapeutic |
| 04/18/2013 | WO2013056232A2 Rxr agonists compounds and methods |
| 04/18/2013 | WO2013056229A1 The use of (2r, 6r)-hydroxynorketamine, (s)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (r,s)- ketamine in the treatment of depression and neuropathic pain |
| 04/18/2013 | WO2013056216A1 Micrornas and methods of using same |
| 04/18/2013 | WO2013056183A1 Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions contianing them |
| 04/18/2013 | WO2013056181A1 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| 04/18/2013 | WO2013056163A1 Beta-lactamase inhibitors |
| 04/18/2013 | WO2013056159A1 Methods and compositions for rapid transbuccal delivery of active agents |
| 04/18/2013 | WO2013056148A2 Methods of using scd1 antagonists |
| 04/18/2013 | WO2013056142A2 Meso-biliverdin compositions and methods |
| 04/18/2013 | WO2013056132A2 Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof |
| 04/18/2013 | WO2013056105A2 INHIBITION OF SPINAL MAMMALIAN TARGET OF RAPAMYCIN (mTOR) REDUCES CANCER PAIN, OPIOID TOLERANCE, AND HYPERALGESIA |
| 04/18/2013 | WO2013056079A1 High affinity beta lactamase inhibitors |
| 04/18/2013 | WO2013056067A1 Compounds for use in the treatment of basal cell carcinoma |
| 04/18/2013 | WO2013056060A1 Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| 04/18/2013 | WO2013056048A2 Nutritional products comprising beta-alanine |
| 04/18/2013 | WO2013056046A1 Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
| 04/18/2013 | WO2013056034A1 Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| 04/18/2013 | WO2013056015A1 Isoindolinone and pyrrolopyridinone derivatives as akt inhibitors |
| 04/18/2013 | WO2013056003A2 Catechol diethers as potent anti-hiv agents |
| 04/18/2013 | WO2013055996A1 Treatment of pharmacological-induced hypochlorhydria |
| 04/18/2013 | WO2013055985A1 Combinatorial compositions and methods of treating hemoglobinopathies |
| 04/18/2013 | WO2013055984A1 Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| 04/18/2013 | WO2013055971A1 Polymers for delivering a substance into a cell |
| 04/18/2013 | WO2013055949A2 Pyrazol-3-ones that activate pro-apoptotic bax |
| 04/18/2013 | WO2013055910A1 Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| 04/18/2013 | WO2013055907A1 Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| 04/18/2013 | WO2013055897A1 8 - carbamoyl - 2 - (2,3- di substituted pyrid - 6 - yl) -1,2,3,4 -tetrahydroisoquinoline derivatives as apoptosis - inducing agents for the treatment of cancer and immune and autoimmune diseases |
| 04/18/2013 | WO2013055834A2 Er stress relievers in beta cell protection |
| 04/18/2013 | WO2013055833A1 Dosage regimen for a sip receptor agonist |
| 04/18/2013 | WO2013055825A2 Guanidinyl-substituted polyamides useful for treating human papilloma virus |
| 04/18/2013 | WO2013055793A1 Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer |
| 04/18/2013 | WO2013055771A1 Thioxothiazolidinone derivatives useful as inhibitors of tdp1 |
| 04/18/2013 | WO2013055734A1 Treatment of degenerative joint disease |
| 04/18/2013 | WO2013055689A1 R(+)-n-methyl-propargyl-aminoindan |
| 04/18/2013 | WO2013055687A2 R(+)-n-formyl-propargyl-aminoindan |
| 04/18/2013 | WO2013055684A1 Rasagiline citramide |
| 04/18/2013 | WO2013055679A2 Method for treating thrombotic disorders using quercetin-containing compositions |
| 04/18/2013 | WO2013055674A1 Method for treating infections |
| 04/18/2013 | WO2013055647A1 Fluorescent dyes |
| 04/18/2013 | WO2013055645A1 5,7-substituted-imidazo[1,2-c]pyrimidines |
| 04/18/2013 | WO2013055595A1 Determining responsiveness of autoimmune patients to dmard treatment |
| 04/18/2013 | WO2013055577A1 Selective androgen receptor modulators |
| 04/18/2013 | WO2013055563A1 Compounds for the treatment of hepatitis c |
| 04/18/2013 | WO2013055528A1 Methods of treating pediatric patients using dexmedetomidine |
| 04/18/2013 | WO2013055386A2 Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome |
| 04/18/2013 | WO2013055385A2 Methods of treating age related disorders |
| 04/18/2013 | WO2013055315A1 Method and compositions for treating skin |
| 04/18/2013 | WO2013055302A1 Effervescent composition comprising n- acetylcysteine and doxophylline or theophylline |